"10.1371_journal.pone.0020740","plos one","2011-06-16T00:00:00Z","Jan Spanholtz; Frank Preijers; Marleen Tordoir; Carel Trilsbeek; Jos Paardekooper; Theo de Witte; Nicolaas Schaap; Harry Dolstra","Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Tumor Immunology, Radboud University Medical Centre, Nijmegen, The Netherlands","Conceived and designed the experiments: JS FP HD. Performed the experiments: JS MT JP CT. Analyzed the data: JS MT CT JP HD FP. Contributed reagents/materials/analysis tools: JS FP. Wrote the paper: JS HD. Revised the manuscript: FP MS TdW.","The work relates to GBGM® medium for ex-vivo generation of NK-cells, which is a commercially available cell culture medium previously developed by Glycostem Therapeutics. Purchase and/or use of GBGM® medium is not restricted by patent rights. Glycostem Therapeutics has acted as sponsor in part of this research. Authors Spanholtz and Tordoir are employees of Glycostem, scientifically directed by Dolstra. Compensation for Dolstras involvement in this project is paid by Glycostem to the overall research budget of RUNMC. RUNMC and Glycostem cooperate on the basis of a research collaboration agreement, which regulates the above interests. Neither Dolstra nor RUNMC have a financial interest in Glycostem. All authors confirm that this does not alter their adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors. The authors agree to make freely available any materials and information associated with their publication that are reasonably requested by others for the purpose of academic, non-commercial research.","2011","06","Jan Spanholtz","JS",8,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
